Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist
References (30)
- et al.
Characterization of the binding of [3H] SCH 23390, a selective D-1 receptor antagonist
(1984) - et al.
Investigation into the nature of the peri-oral movements induced by 2-(N,M-dipropyl)amino-5,6-dihydroxytetraline
Eur. J. Pharmacol.
(1977) β-Adrenoceptors in human brain labelled with [3H] dihydroalprenolol and [3H] CGP 12177
Eur. J. Pharmacol.
(1989)- et al.
Autonomic and haemodynamic responses to SK&F 101468 (ropinirole), a DA2 agonist, in anaesthetised cats
Eur. J. Pharmacol.
(1990) Closer to Parkinson's disease: MPTP and the aging nervous system
Trends Pharmacol. Sci.
(1987)- et al.
Effect of apomorphine on motility in rats
Eur. J. Pharmacol.
(1972) - et al.
‘On-Off’ effects in patients with Parkinson's disease on chronic levadopa therapy
Lancet
(1976) - et al.
Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease
Lancet
(1986) - et al.
Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways
Biochem. Pharmacol.
(1983) - et al.
Subcutaneous apomorphine in parkinsonian On-Off fluctuations
Lancet
(1988)
(+)-4-Propyl-9-hydroxynaphthoxaxine (PHNO), a new dopaminomimetic, in treatment of Parkinsonism
Lancet
(1985)
Drugs acting on the brain dopamine receptors: A conceptual re-evaluation five years after the first selective D1 antagonist
Pharmacol. Ther.
(1989)
Serotonin and lysergic acid diethyline binding in rat brain membranes: relationship to postsynaptic serotonin receptors
Mol. Pharmacol.
(1976)
A model of nausea and emesis in the common marmoset
Br. J. Pharmacol.
(1986)
Effects of chronic oral administration of antidepressants, desmethylimiframine and zimelidine on rat cortical GABAB binding sites: a comparison with 5-HT2 binding site changes
Br. J. Pharmacol.
(1988)
Cited by (158)
The complex molecular pharmacology of the dopamine D<inf>2</inf> receptor: Implications for pramipexole, ropinirole, and rotigotine
2023, Pharmacology and TherapeuticsDopamine D<inf>2</inf>L receptor density influences the recruitment of β-arrestin2 and G<inf>i</inf>1 induced by antiparkinsonian drugs
2022, NeuropharmacologyCitation Excerpt :Notwithstanding, it is important to state that our interpretation arises from experiments performed on recombinant cell lines. In a more clinically-oriented framework, the multifaceted aspects of the tested compounds with respect to dopaminergic pharmacology as a whole shall not be overlooked, especially as the examined dopamine agonists have a remarkable affinity for dopamine receptors other than D2 (Eden et al., 1991; Mierau et al., 1995; Wood et al., 2015). Considering our findings from a more holistic perspective might also yield insights of relevant interest in neuropharmacology.
Dopamine receptors in emesis: Molecular mechanisms and potential therapeutic function
2020, Pharmacological ResearchA novel tool for structure assignment of hydroxylated metabolites of (arylpiperazinylbutyl)oxindole derivatives based on relative HPLC retention times
2019, Journal of Pharmaceutical and Biomedical Analysis
- 1
Present address: Toxicol Laboratories, Ledbury, Herefordshire, HR8 1LH.
Copyright © 1991 Published by Elsevier Inc.